Metabolic to spend $2.1m grant on clinical trials
Wednesday, 06 August, 2003
Metabolic Pharmaceuticals (ASX:MBP) has been granted an R&D Start grant of up to AUD$2.1 million to conduct its Phase IIb clinical trial for its obesity drug AOD9604.
According to CEO Chris Belyea, the grant will deliver welcome support to the trial and would leave the company in a strong financial position at the end of the trial.
It's the first grant of its kind received by the company, Belyea said. He noted that the grant would support trial expenses in Australia rather than overseas costs associated with the trial.
Metabolic's three-month trial is to be carried out in 300 patients at five Australian hospitals. Screening of patients is expected to begin in September, and the first patients will begin taking the drug in October, Belyea said.
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
